Industry
Biotechnology
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Insights
June 19, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Insights
June 18, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
June 17, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 12:46 pm
Portfolio Pulse from Benzinga Newsdesk
June 04, 2024 | 11:17 am
Portfolio Pulse from Benzinga Newsdesk
June 03, 2024 | 12:47 pm
Portfolio Pulse from Benzinga Newsdesk
May 28, 2024 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 9:03 pm
Portfolio Pulse from Benzinga Newsdesk
May 06, 2024 | 9:12 pm
Portfolio Pulse from Benzinga Newsdesk
April 03, 2024 | 10:41 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.